aCCI-HBV-ACLF:一种预测乙型肝炎病毒相关慢加急性肝衰竭的新型模型
本研究纳入906例乙型肝炎病毒相关慢加急性肝衰竭(HBV-ACLF)患者,按入院时间7:3分为训练队列和时间验证队列,利用年龄调整的Charlson共病指数(aCCI)等指标构建aCCI-HBV-ACLF预后模型,并在时间验证队列和外部验证队列中验证。模型对28天和90天无移植死亡率的预测曲线下面积在训练队列分别为0.859和0.822,时间验证队列分别为0.869和0.850,外部验证队列分别为0.868和0.888。
要点
- aCCI-HBV-ACLF模型由总胆红素、中性粒细胞、国际标准化比值和aCCI构成。
- 训练队列28天和90天无移植死亡率的AUC分别为0.859和0.822。
- 时间验证队列AUC分别为0.869和0.850,外部验证队列分别为0.868和0.888。
核心结论
- 本研究提出aCCI-HBV-ACLF新型预后模型,对HBV-ACLF患者28天和90天无移植死亡率具有优良预测能力。
研究设计与样本
- 纳入906例患者,按入院时间顺序以7:3分为训练队列和时间验证队列,并在外部验证队列中验证。
- 训练队列采用单因素分析、逻辑回归分析和LASSO回归分析构建预后模型。
主要发现
- 总胆红素、中性粒细胞、国际标准化比值和aCCI与28天无移植死亡率显著相关。
- 训练队列AUC:28天死亡率0.859,90天死亡率0.822。
- 时间验证队列AUC:28天死亡率0.869,90天死亡率0.850。
- 外部验证队列AUC:28天死亡率0.868,90天死亡率0.888。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early identification of hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) holds crucial importance in guiding clinical management and reducing mortality. However, existing scoring systems often overlook patient's underlying clinical condition, which significantly impacts prognosis. AIMS: Use the age-adjusted Charlson comorbidity index (aCCI) to evaluate the patient's complications to develop a more precise model for predicting transplant-free mortality in HBV-ACLF patients. METHODS: Nine hundred and six patients were included for investigation and were segregated into a training cohort and a temporal validation cohort according to the chronological order of admission in a ratio of 7:3. In the training cohort, univariate analysis, logistic regression analysis and LASSO regression analysis were used to construct a prognostic model and it was subsequently validated in a temporal validation cohort and an external validation cohort. RESULTS: We found total bilirubin, neutrophils, international normalised ratio and aCCI exhibited significant associations with 28-day transplant-free mortality and established a novel prognostic model, named aCCI-HBV-ACLF. The model demonstrated strong predictive performance, with area under the receiver operating characteristic curve (ROC) values of 0.859 for 28-day mortality, 0.822 for 90-day mortality. In the temporal validation cohort, aCCI-HBV-ACLF achieved area under the ROC values of 0.869 for 28-day mortality and 0.850 for 90-day mortality. In the external validation cohort, aCCI-HBV-ACLF had area under the ROC values of 0.868 for 28-day mortality and 0.888 for 90-day mortality. CONCLUSIONS: This study proposes a new prognostic model, which achieved excellent predictive ability for 28-/90-day transplant-free mortality rates among patients with HBV-ACLF.
引用
- Chen X, Gao F, Pan Q, et al. aCCI-HBV-ACLF: A Novel Predictive Model for Hepatitis B Virus-Related Acute-On-Chronic Liver Failure. Aliment Pharmacol Ther. 2024. PMID: 39460434. doi:10.1111/apt.18347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。